Research brief · published remissions & approvals · 2022–2026

Cancer is being cured without chemo. Here are the papers.

Not vibes. Not “someone on X said.” Peer-reviewed trials, FDA and global approvals, and company-published efficacy data where tumors vanished, patients avoided surgery/radiation/chemo, or durable remissions were measured. Separate from the antiparasitic research map.

100%
clinical CR · dMMR rectal cancer · dostarlimab alone · NEJM
60–90%
complete remission · CAR-T in relapsed B-cell leukemias
71%
complete response · ANKTIVA + BCG bladder CIS
49%
lower recurrence/death risk · mRNA vaccine + PD-1 · melanoma 5-yr
Focus: immunotherapy · cell therapy · mRNA vaccines · IL-15 Format: claim → number → paper link Companion: antiparasitic research brief

The claim, stated plainly

What the published record actually establishes.

Chemotherapy is not the only path to curing or remitting cancer. That has been true for years, and the 2022–2026 literature makes it impossible to deny without ignoring data.

Immunotherapy (PD-1 blockade), engineered T cells (CAR-T, TCR-T, TIL), cytokine agonists (IL-15), and personalized mRNA neoantigen vaccines have produced complete responses, organ-sparing cures, multi-year remissions, and regulatory approvals — including cases with no chemo, no radiation, and no surgery. Scope matters (biomarker, stage, prior therapy). The phenomenon does not.

If you only open five things

Highest signal density for a trained reader. Each link is primary or regulatory.

NEJM · 100% CR
Dostarlimab in dMMR rectal cancer

No chemo, radiation, or surgery. Every consecutive patient clinical complete response.
NEJM 2025 · expansion
Nonoperative PD-1 in dMMR solid tumors

All 49 patients completing treatment: clinical complete response; organ preservation path.
FDA · solid tumor cell Rx
Tecelra (afami-cel) — TCR-T

First engineered T-cell therapy approved for a solid tumor (synovial sarcoma).
5-year data
mRNA-4157 + Keytruda · melanoma

49% reduction in recurrence or death vs Keytruda alone at median 5 years.
Global approval · 2026
ANKTIVA bladder + lung (UAE)

IL-15 agonist; 71% CR in bladder CIS trial data; multi-country footprint.

Slam dunks

If someone still says there are no non-chemo cures, send them these three.

Complete remission No chemo · no radiation · no surgery Phase 2 · NEJM

Dostarlimab (Jemperli) — mismatch repair–deficient rectal cancer

100% clinical complete response in consecutive patients. Tumors gone on MRI, PET, endoscopy, exam, and biopsy.

Memorial Sloan Kettering. Single-agent PD-1 antibody for 6 months in locally advanced dMMR rectal cancer. Every patient who completed therapy achieved clinical complete response. None required the usual chemo-radiation-surgery sequence. Lead investigator Andrea Cercek described it as what cancer doctors dream of — better efficacy, almost no toxicity. The 2025 NEJM follow-on expanded nonoperative PD-1 management across dMMR solid tumors amenable to curative surgery: all 49 patients in the primary cohort who completed treatment had clinical complete response.

Drug: dostarlimab (GSK) Who: dMMR / MSI-high only Why it matters: published organ-sparing cure path
NEJM 2022 PubMed NEJM 2025 expansion ASCO Post
Complete remission rates FDA-approved class Blood cancers

CAR-T cell therapy — relapsed/refractory B-cell malignancies

Complete remission rates commonly 60–90% in approved leukemia settings. Not experimental folklore — standard of care.

Patient T cells engineered to kill cancer. Multiple commercial products worldwide. In relapsed/refractory B-cell ALL and related diseases, high complete remission rates are the documented baseline (e.g. ELIANA pivotal: overall remission rate ~81%). Solid tumors are harder — and still moving: GD2 CAR-T in pediatric neuroblastoma reported 63% ORR with multiple complete responses; claudin18.2 CAR-T in GI tumors ~49% ORR in cited cohorts.

Examples: Kymriah, Yescarta, Tecartus, Breyanzi, Carvykti… Solid tumor edge: advancing through 2025–2026
CAR-T landscape 2026 Nature 2025 review Frontiers solid-tumor CAR-T
FDA + global approvals 71% CR · bladder CIS ImmunityBio

ANKTIVA (nogapendekin alfa inbakicept) — IL-15 superagonist

FDA-approved for BCG-unresponsive NMIBC CIS. UAE (July 2026) authorized bladder (CIS + papillary) and metastatic NSCLC after checkpoint failure.

Not chemotherapy. An IL-15 receptor agonist that expands NK cells, T cells, and memory T cells. QUILT-3.032: ~71% complete response in BCG-unresponsive CIS with BCG combo; durable bladder preservation in long-term follow-up. QUILT-3.055 (checkpoint-refractory NSCLC): median OS 14.6 months (16.2 in patients recovering lymphocyte counts). Commercial biotech with trial IDs and regulatory labels — the program dominating a large share of 2026 X coverage.

Company: ImmunityBio (IBRX) Trials: QUILT-3.032 · QUILT-3.055 · QUILT-2.023
UAE dual authorization Bladder preservation data NSCLC OS / lymphopenia

Cell therapies for solid tumors — now approved

“CAR-T only works in blood cancers” is outdated. Solid-tumor cell products are on labels.

FDA · Tecelra

Afamitresgene autoleucel (afami-cel)

First TCR-T for solid tumor

MAGE-A4–directed engineered T cells for unresectable/metastatic synovial sarcoma (HLA-A*02 + MAGE-A4+). Accelerated approval Aug 2024; full approval and adolescent expansion reported 2026. ORR ~43% in efficacy set.

FDA PubMed summary NCI
FDA · Amtagvi

Lifileucel (TIL therapy)

First TIL therapy · solid tumor

Autologous tumor-infiltrating lymphocytes for advanced melanoma after PD-1 (± BRAF/MEK). FDA accelerated approval Feb 2024. Trial ORR ~31.5%; real-world commercial series later reported ~49% ORR. One-time cell infusion.

FDA PubMed summary NCI
Published signal

GD2 CAR-T — neuroblastoma

63% ORR · multiple CRs

Heavily pretreated pediatric neuroblastoma (NCT03373097): overall response 63%; 9 complete + 8 partial responses in 27 patients; multi-year survival signals at recommended dose.

Nature review
Published signal

Claudin18.2 CAR-T — GI tumors

48.6% ORR · 73% DCR

Gastrointestinal cancers (NCT04196413, n=37 in cited cohort): objective response and disease-control rates that put solid-tumor CAR-T beyond case reports.

Nature 2025 Frontiers

Personalized mRNA cancer vaccines

Same platform class as COVID vaccines, aimed at each patient’s tumor neoantigens. Measured recurrence and survival endpoints — not prevention folklore.

Phase 2b · 5-year follow-up Moderna + Merck

Intismeran autogene (mRNA-4157 / V940) + pembrolizumab — high-risk melanoma

At median 5 years: 49% reduction in risk of recurrence or death vs Keytruda alone. 59% reduction in distant metastasis or death.

KEYNOTE-942 / mRNA-4157-P201. Individualized neoantigen mRNA therapy after complete resection of stage III/IV melanoma. Benefit held through five-year planned follow-up (ASCO 2026 / company and journal presentation). Large confirmatory program running across lung, kidney, bladder, pancreas.

Merck/Moderna 5-year data Fierce Biotech Reuters 2026 landscape
Phase 1 · long follow-up MSK · pancreatic cancer

Autogene cevumeran — personalized mRNA neoantigen vaccine in PDAC

Vaccine responders: multi-year survival with low recurrence. Non-responders: much worse. Strong enough to open randomized Phase 2.

Memorial Sloan Kettering phase 1 (resected pancreatic cancer): about half mounted strong T-cell responses. Among responders, roughly 7 of 8 still alive 4–6 years later in follow-up reports; vaccine-expanded CD8 clones persisted years. 3-year recurrence-free survival reported ~75% in responders vs ~12.5% in non-responders (HR 0.14). Phase 2 IMCODE003 (NCT05968326) ongoing. For a disease with ~13% five-year survival historically, that split is the point.

MSKCC long-term follow-up 2025 PDAC vaccine review IMCODE003 Phase 2

Program map — what 2026 X coverage is pointing at

A lot of viral posts recycle the same real programs. Here’s the map so the signal isn’t lost in spam accounts.

Program What happened Where to click
Dostarlimab · GSK / MSK 100% clinical CR in dMMR rectal; organ preservation; NEJM NEJM 2022 · NEJM 2025
ANKTIVA · ImmunityBio FDA bladder; UAE bladder + lung 2026; 71% CR CIS; OS signal post-checkpoint lung UAE approval
Tecelra · afami-cel First engineered T-cell therapy approved for a solid tumor (synovial sarcoma) FDA
Amtagvi · lifileucel · Iovance First TIL therapy; metastatic melanoma after PD-1 FDA
mRNA-4157 + Keytruda · Moderna / Merck 49% lower recurrence/death risk at 5 years vs Keytruda alone 5-year data
Autogene cevumeran · MSK Pancreatic neoantigen mRNA; multi-year survival in immune responders MSKCC
Commercial CAR-T (multiple) 60–90% CR class results in B-cell malignancies; expanding solid-tumor trials 2025 review
Checkpoint inhibitors broadly Long-term remissions in melanoma, lung, MSI-high subsets — foundation of the above dMMR exemplar

What this establishes

Precision is not the same thing as denial.

Established by the data

Cancer can and does go to complete remission without chemo in defined settings. The immune system, unlocked or engineered, can eradicate tumors. Multiple companies and academic centers have published and commercialized this. 2024–2026 is a wave of solid-tumor cell therapy and mRNA neoantigen maturation — not a rumor cycle.

Still required for honest reading

Biomarkers matter (dMMR, HLA type, MAGE-A4, GD2, etc.). That is precision, not an escape hatch. Some results are single-arm or mid-phase; confirmatory trials scale wins — they do not erase them. Cost and access are political problems layered on top of scientific success.

Companion brief

Different claim surface. Different evidence spine. Send both.

Separate dossier for repurposed antiparasitics (ivermectin, mebendazole, fenbendazole) and their paper map: open antiparasitics brief in this same folder.